Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
Ontology highlight
ABSTRACT: Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was the most successful in having the longest temporal window of clinical use, showing a high degree of resiliency to SARS-CoV-2 evolution interrupted only by the appearance of the BA.2.86* variant of interest (VOI). This success undoubtedly reflects rational selection to target a highly conserved epitope in coronavirus Spike proteins. We review here the efficacy of sotrovimab against different SARS-CoV-2 variants in outpatients and inpatients, discussing both randomized controlled trials and real-world evidence. Although it could not be anticipated at the time of its development and introduction, sotrovimab's use in immunocompromised individuals who harbor large populations of variant viruses created the co
SUBMITTER: Focosi D
PROVIDER: S-EPMC10891757 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA